Advertisement

Endocrine

, Volume 25, Issue 3, pp 203–206 | Cite as

Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test

  • Yutaka Mori
  • Genshin Kuriyama
  • Naoko Tajima
Article

Abstract

To elucidate the role of early insulin response in postprandial hyperlipidemia, we examined triglyceride (TG) and remnant-like particle triglyceride (RLP-TG) levels, using a meal tolerance test (MTT) with or without the administration of nateglinide (NAT). The MTTs were performed 2 d apart in 36 drug-naive patients with type 2 diabetes who had been hospitalized for glycemic control while receiving diet therapy. Before the second MTT, patients were treated with 90 mg NAT. Treatment with NAT was associated with a significant increase in insulin levels in the treated patients 1 h after the test meal, compared to levels in non-treatment. NAT treatment was also associated with a significant decrease in the level of free fatty acids 1 and 2 h after the meal, and with a significant decrease in plasma glucose levels 1, 2, and 4 h after the meal, compared to those in non-treatment. During the first MTT with NAT non-treatment, 13 patients showed serum TG levels of 200 mg/dL or greater when measured 2 h after the meal. In these 13 patients, NAT administration produced a significant decrease in TG levels 1, 2, and 6 h after the meal, as well as a significant reduction in RLP-TG levels 1 and 2 h after the meal. NAT administration was also associated with significant reductions in area under the curve (ΔAUC) for TG and RLP-TG. These results suggest that, in a clinical setting, the early insulin response is closely associated with both postprandial glucose and postprandial lipid metabolism in Japanese patients with type 2 diabetes.

Key Words

Nateglinide remnant-like particle (RLP) triglyceride type 2 diabetes postprandial hyperlipidemia meal tolerance test 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    The DECODE Study Group. European Diabetes Epidemiology Group. (1999). Lancet 354, 617–621.CrossRefGoogle Scholar
  2. 2.
    DECODE Study Group, the European Diabetes Epidemiology Group. (2001). Arch. Intern. Med. 161, 397–405.CrossRefGoogle Scholar
  3. 3.
    Teno, S., Uto, Y., Nagashima, H., et al. (2000). Diabetes Care 23, 1401–1406.PubMedCrossRefGoogle Scholar
  4. 4.
    Ross, R. (1993). Nature 362, 801–809.PubMedCrossRefGoogle Scholar
  5. 5.
    Ceriello, A., Taboga, C., Tonutti, L., et al. (2002). Circulation 106, 1211–1218.PubMedCrossRefGoogle Scholar
  6. 6.
    Tanaka, A., Tomie, N., Nakano, T., et al. (1998). Clin. Chim. Acta 275, 43–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Ai, M., Tanaka, A., Ogita, K., et al. (2000). J. Clin. Endocrinol. Metab. 85, 3557–3560.PubMedCrossRefGoogle Scholar
  8. 8.
    Ai, M., Tanaka, A., Ogita, K., et al. (2001). J. Am. Coll. Cardiol. 38, 1628–1632.PubMedCrossRefGoogle Scholar
  9. 9.
    McNamara, J. R., Shah, P. K., Nakajima, K., et al. (2001). Atherosclerosis 154, 229–236.PubMedCrossRefGoogle Scholar
  10. 10.
    Kugiyama, K., Doi, H., Takazoe, K., et al. (1999). Circulation 99, 2858–2860.PubMedGoogle Scholar
  11. 11.
    Schaefer, E. J., McNamara, J. R., Shah, P. K., et al. (2002). Diabetes Care 25, 989–994.PubMedCrossRefGoogle Scholar
  12. 12.
    Horton, E. S., Clinkingbeard, C., Gatlin, M., Foley, J., Mallows, S., and Shen, S. (2000). Diabetes Care 23, 1660–1665.PubMedCrossRefGoogle Scholar
  13. 13.
    Mine, T., Miura, K., Kitahara, Y., Okano, A., and Kawamori, R. (2002). Biol. Pharm. Bull. 25, 1414–1416.CrossRefGoogle Scholar
  14. 14.
    Esposito, K., Giugliano, D., Nappo, F., Marfella, R., and Campanian Postprandial Hyperglycemia Study Group. (2004). Circulation 110, 214–219.PubMedCrossRefGoogle Scholar
  15. 15.
    Vakkilainen, J., Mero, N., Schweizer, A., Foley, J. E., and Taskinen, M.-R. (2002). Diabetes Metab. Res. Rev. 18, 484–490.PubMedCrossRefGoogle Scholar
  16. 16.
    Mori, Y., Kitahara, Y., Miura, K., Mine, T., and Tajima, N. (2004). Diabetes Obes. Metab. 6, 422–431.PubMedCrossRefGoogle Scholar
  17. 17.
    Mori, Y., Kitahara, Y., Miura, K., and Tajima, N. (2004). Endocrine 23, 39–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Dimitriadis, G., Boutati, E., Lambadiari, V., et al. (2004). Eur. J. Clin. Invest. 34, 490–497.PubMedCrossRefGoogle Scholar
  19. 19.
    Califf, R. M. (2003). Eur. Heart J. Suppl. 5(Suppl C), C13-C18.CrossRefGoogle Scholar
  20. 20.
    Ogawa, S., Takeuchi, K., Sugimura, K., et al. (2000). Metabolism 49, 331–334.PubMedCrossRefGoogle Scholar
  21. 21.
    Banauch, D., Brummer, W., Ebeling, W., et al. (1975). Z. Klin. Chem. Klin. Biochem. 13, 101–107.PubMedGoogle Scholar
  22. 22.
    Nakajima, K., Saito, T., Tamura, A., et al. (1993). Clin. Chim. Acta 223, 53–71.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2004

Authors and Affiliations

  1. 1.Division of Diabetes and Endocrinology, Department of Internal MedicineThe Jikei University School of MedicineTokyoJapan
  2. 2.Department of Internal MedicineNational Hospital Organization, Utsunomiya National HospitalTochigiJapan

Personalised recommendations